Cargando…

Effect of ethyl acetate extract of usnea longissima on esophagogastric adenocarcinoma in rats

PURPOSE: To investigate the effects of the EtOAc extract of U. longissima which is uninvestigated previously on esophagogastric cancer induced in rats with N-methyl-N-nitro-N-nitrosoguanidin (MNNG). METHODS: The anticancer activity of EtOAc extract of U. longissima was examined in the esophagogastri...

Descripción completa

Detalles Bibliográficos
Autores principales: Mammadov, Renad, Suleyman, Bahadir, Altuner, Durdu, Demirci, Elif, Cetin, Nihal, Yilmaz, Adnan, Baykal, Huseyin, Alpcan, Hilal, Turumtay, Emine Akyuz, Suleyman, Halis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585887/
https://www.ncbi.nlm.nih.gov/pubmed/30892391
http://dx.doi.org/10.1590/s0102-865020190030000005
Descripción
Sumario:PURPOSE: To investigate the effects of the EtOAc extract of U. longissima which is uninvestigated previously on esophagogastric cancer induced in rats with N-methyl-N-nitro-N-nitrosoguanidin (MNNG). METHODS: The anticancer activity of EtOAc extract of U. longissima was examined in the esophagogastric adenocarcinoma models induced in rats with MNNG. EtOAc extract of U. longissima, 50 and 100 mg/kg oral doses were administered once daily for six months. MNNG induced differentiated and undifferentiated type adenocarcinomas in the esophageal and gastric tissues of rats. RESULTS: EtOAc extract of U. longissima obtained from U. longissima prevented gastric and esophageal cancerogenesis induced in rats with MNNG. EtOAc extract of U. longissima did not have a lethal effect at doses of 500, 1000 and 2000 mg/kg. The prominent anticarcinogenic activity of EtOAc extract of U. longissima 50 and 100 mg/kg suggests that it is not toxic and it is selective to the cancer tissue. CONCLUSION: This information may shed light on clinical implementation of EtOAc extract of U. longissima in future.